Anti-tumor immunity generated by tumor cells engineered to express B7-1 via retroviral or adenoviral gene transfer
- 11 December 1998
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 135 (1) , 1-10
- https://doi.org/10.1016/s0304-3835(98)00274-2
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- CD28/B7 SYSTEM OF T CELL COSTIMULATIONAnnual Review of Immunology, 1996
- Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation?Cell, 1995
- Tolerance, Danger, and the Extended FamilyAnnual Review of Immunology, 1994
- Tumor Antigens Recognized by T LymphocytesAnnual Review of Immunology, 1994
- The Role of the CD28 Receptor During T Cell Responses to AntigenAnnual Review of Immunology, 1993
- Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma CellsScience, 1993
- Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4Cell, 1992
- Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5Journal of General Virology, 1977
- ANTIGENIC PROPERTIES OF MURINE SARCOMA VIRUS-TRANSFORMED BALB/3T3 NONPRODUCER CELLSThe Journal of Experimental Medicine, 1972
- Characterization of Murine Sarcoma Virus (KIRSTEN) Transformation of Mouse and Human CellsJournal of General Virology, 1971